January 9, 2023 — When we were little, our parents told us to take our vitamins so we could grow big and strong. Now, researchers from Japan find that one particular supplement may even fix a broken ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
-
-
September 21, 2022 — Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the provisional ...
-
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD) study were presented as late-breaking clinical research ...
-
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The ...
January 9, 2023 — When we were little, our parents told us to take our vitamins so we could grow big and strong. Now ...
January 09, 2023
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent (DC ...
January 02, 2023
December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...
December 23, 2022
September 21, 2022
July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...
July 05, 2022
June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...
June 02, 2022
May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...
May 20, 2022
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...
May 20, 2022
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...
February 16, 2022
Patients With Diabetes Undergoing PCI Have Less Target Lesion Failure With Amphilimus-eluting Stents
November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...
November 09, 2021
October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...
October 20, 2021
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...
September 01, 2021
June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug ...
June 30, 2021
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...
June 07, 2021
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...
April 14, 2021© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now